Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by Rothschild Investment LLC

Rothschild Investment LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 128,416 shares of the biopharmaceutical company's stock after selling 13,792 shares during the period. Rothschild Investment LLC's holdings in Pfizer were worth $3,254,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Tallon Kerry Patrick bought a new position in shares of Pfizer during the fourth quarter worth about $509,000. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Synergy Asset Management LLC bought a new position in shares of Pfizer during the fourth quarter worth about $63,000. Finally, Crews Bank & Trust bought a new position in shares of Pfizer during the fourth quarter worth about $534,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE traded up $0.01 during trading hours on Friday, hitting $23.46. 56,576,195 shares of the company were exchanged, compared to its average volume of 41,090,161. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $133.38 billion, a PE ratio of 16.64, a PEG ratio of 0.64 and a beta of 0.58. The firm has a fifty day simple moving average of $23.12 and a 200-day simple moving average of $25.06. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.82 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.33%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on PFE shares. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.